Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FLT3 K663Q |
| Gene Variant Detail | |
| Relevant Treatment Approaches | FLT3 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FLT3 K663Q | hematologic cancer | sensitive | FLT3 Inhibitor | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) resulted in inhibition of cell proliferation, reduced phosphorylation of Flt3, Akt, Mapk, and Stat5, and induced apoptosis in transformed cells expressing FLT3 K663Q in culture (PMID: 16990784). | 16990784 |
| FLT3 K663Q | hematologic cancer | sensitive | FLT3 Inhibitor | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870). | 40196870 |
| FLT3 K663Q | hematologic cancer | sensitive | FLT3 Inhibitor | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870). | 40196870 |
| FLT3 K663Q | hematologic cancer | sensitive | FLT3 Inhibitor | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870). | 40196870 |